Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Berk

Showing results (121-130 of 1,305) with videos related to

Pageof 131
Sort By:
Current Reviews in Clinical and Experimental Pharmacology|May 6, 2024
Current Pharmacotherapies for Smoking Cessation and Promising Emerging DrugsSeetal Dodd, Jodie Harper, Michael Berk
Harvard Review of Psychiatry|May 5, 2016
Integrating Early Intervention for Borderline Personality Disorder and Mood DisordersAndrew M Chanen, Michael Berk, Katherine Thompson
The American Journal of Psychiatry|July 4, 2006
Depression and mania in mixed statesMichael Berk, Seetal Dodd, Gin S Malhi
The Lancet. Psychiatry|May 24, 2020
Anti-inflammatory treatment of bipolar depression: promise and disappointmentMichael Berk, Eduard Vieta, Olivia M Dean
The Australian and New Zealand Journal of Psychiatry|February 16, 2006
Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?Philippe Conus, Michael Berk, Patrick D McGorry
JAMA Psychiatry|May 25, 2017
First-Episode Schizophrenia and Diabetes RiskChiara C Bortolasci, Michael Berk, Ken Walder
The Medical Journal of Australia|November 6, 2014
Difficult-to-treat depressionDavid J Castle, Leon Piterman, Michael Berk
The Australian and New Zealand Journal of Psychiatry|June 14, 2013
A Royal gift to prevention effortsMichael Berk, Steven Moylan, Felice N Jacka
The Australian and New Zealand Journal of Psychiatry|December 17, 2009
Is lithium in a class of its own? A brief profile of its clinical useGin S Malhi, Danielle Adams, Michael Berk
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2011
Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidenceDavid A Camfield, Jerome Sarris, Michael Berk
Pageof 131

Showing results (121-130 of 1,305) with videos related to

Sort By:
Pageof 131
Current Reviews in Clinical and Experimental Pharmacology|May 6, 2024
Current Pharmacotherapies for Smoking Cessation and Promising Emerging DrugsSeetal Dodd, Jodie Harper, Michael Berk
Harvard Review of Psychiatry|May 5, 2016
Integrating Early Intervention for Borderline Personality Disorder and Mood DisordersAndrew M Chanen, Michael Berk, Katherine Thompson
The American Journal of Psychiatry|July 4, 2006
Depression and mania in mixed statesMichael Berk, Seetal Dodd, Gin S Malhi
The Lancet. Psychiatry|May 24, 2020
Anti-inflammatory treatment of bipolar depression: promise and disappointmentMichael Berk, Eduard Vieta, Olivia M Dean
The Australian and New Zealand Journal of Psychiatry|February 16, 2006
Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?Philippe Conus, Michael Berk, Patrick D McGorry
JAMA Psychiatry|May 25, 2017
First-Episode Schizophrenia and Diabetes RiskChiara C Bortolasci, Michael Berk, Ken Walder
The Medical Journal of Australia|November 6, 2014
Difficult-to-treat depressionDavid J Castle, Leon Piterman, Michael Berk
The Australian and New Zealand Journal of Psychiatry|June 14, 2013
A Royal gift to prevention effortsMichael Berk, Steven Moylan, Felice N Jacka
The Australian and New Zealand Journal of Psychiatry|December 17, 2009
Is lithium in a class of its own? A brief profile of its clinical useGin S Malhi, Danielle Adams, Michael Berk
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2011
Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidenceDavid A Camfield, Jerome Sarris, Michael Berk
Pageof 131